<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2026-41-2-94-102</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-3166</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Миокардит как сочетанное заболевание у пациентов с постинфарктным кардиосклерозом при острой декомпенсации сердечной недостаточности</article-title><trans-title-group xml:lang="en"><trans-title>Myocarditis as a concomitant condition in patients with post-infarction myocardial fibrosis and acute decompensated heart failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9409-9085</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кручинкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruchinkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кручинкина Екатерина Владимировна - канд. мед. наук, научный сотрудник, врач-кардиолог, отделение неотложной кардиологии, НИИ кардиологии Томского НИМЦ.</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Ekaterina V. Kruchinkina - Cand. Sci. (Med.), Research Scientist, Cardiologist, Department of Emergency Cardiology, Cardiology Research Institute, Tomsk NRMC.</p><p>111a, Kievskaya str., Tomsk, 634012</p></bio><email xlink:type="simple">katy990@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8543-6027</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanov</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Степанов Иван Вадимович - канд. мед. наук, заведующий патологоанатомическим отделением, НИИ кардиологии Томского НИМЦ.</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Ivan V. Stepanov - Cand. Sci. (Med.), Head of Pathological Department, Cardiology Research Institute, Tomsk NRMC.</p><p>111a, Kievskaya str., Tomsk, 634012</p></bio><email xlink:type="simple">i_v_stepanov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3699-4807</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вышлов</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vyshlov</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вышлов Евгений Викторович - д-р мед. наук, ведущий научный сотрудник, отделение неотложной кардиологии, НИИ кардиологии Томского НИМЦ.</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Evgeny V. Vyshlov - Dr. Sci. (Med.), Leading Research Scientist, Department of Emergency Cardiology, Cardiology Research Institute, Tomsk NRMC.</p><p>111a, Kievskaya str., Tomsk, 634012</p></bio><email xlink:type="simple">evv@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4358-7329</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рябов Вячеслав Валерьевич - д-р мед. наук, профессор, чл.-корр. РАН, заместитель директора по научной и лечебной работе, заведующий отделением неотложной кардиологии, НИИ кардиологии Томского НИМЦ.</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Vyacheslav V. Ryabov - Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director for Research and Clinical Work, Head of the Emergency Cardiology Department, Cardiology Research Institute, Tomsk NRMC.</p><p>111a, Kievskaya str., Tomsk, 634012</p></bio><email xlink:type="simple">rvvt@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук (НИИ кардиологии Томского НИМЦ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Cardiology Research Institute, Tomsk NRMC)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>09</day><month>07</month><year>2026</year></pub-date><volume>41</volume><issue>2</issue><fpage>94</fpage><lpage>102</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кручинкина Е.В., Степанов И.В., Вышлов Е.В., Рябов В.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Кручинкина Е.В., Степанов И.В., Вышлов Е.В., Рябов В.В.</copyright-holder><copyright-holder xml:lang="en">Kruchinkina E.V., Stepanov I.V., Vyshlov E.V., Ryabov V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/3166">https://www.sibjcem.ru/jour/article/view/3166</self-uri><abstract><sec><title>Введение</title><p>Введение. Острая декомпенсация сердечной недостаточности (ОДСН) у пациентов с постинфарктным кардиосклерозом даже при ранее выполненной оптимальной коронарной реваскуляризации, как правило, рассматривается как проявление прогрессирования ишемической болезни сердца. Вместе с тем в клинической практике острая декомпенсация может быть обусловлена и неишемическими механизмами, в частности миокардитом. Такое сочетание заболеваний представляется особенно значимым у пациентов со сниженной фракцией выброса левого желудочка и коронарной реваскуляризацией в анамнезе при отсутствии признаков текущей ишемии миокарда.</p></sec><sec><title>Цель</title><p>Цель: оценить частоту выявления миокардита и экспрессии вирусных антигенов в миокарде у пациентов с ОДСН, сниженной фракцией выброса левого желудочка, постинфарктным кардиосклерозом и коронарной реваскуляризацией в анамнезе.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 26 пациентов, госпитализированных с ОДСН. Критериями исключения являлись острый коронарный синдром и состояния, способные самостоятельно вызвать декомпенсацию сердечной недостаточности, включая анемию, пневмонию, сепсис, грипп, декомпенсацию сахарного диабета, онкологические заболевания, кахексию и выраженные пороки клапанов сердца. Медиана фракции выброса левого желудочка составила 29,5% (22,0; 32,0). Всем пациентам выполнена трансторакальная эхокардиография, инвазивная коронарогафия, эндомиокардиальная биопсия правого желудочка. Для выявления воспаления миокарда и экспрессии вирусного антигена проведено патогистологическое и иммуногистохимическое исследование.</p></sec><sec><title>Результаты</title><p>Результаты. Миокардит был диагностирован у 18 пациентов (69%), включая вирусный миокардит – у 13 (50%), вирусно-аутоиммунный – у 3 (12%) и аутоиммунный – у 1 пациента (4%). Экспрессия вирусных антигенов в миокарде выявлялась в 89% случаев. Частота обнаружения вирусных антигенов составила: энтеровирус – 77%, вирус герпеса человека 1-го типа – 8%, 2-го типа – 8%, 6-го типа – 50%, вирус Эпштейна – Барра – 23%, цитомегаловирус – 8%; парвовирус B19 и аденовирус выявлены не были. Экспрессия вирусных антигенов отмечалась у 94% пациентов с миокардитом (за исключением одного случая аутоиммунного миокардита) и у 75% пациентов без гистологических признаков воспаления миокарда.</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с ОДСН со сниженной фракцией выброса левого желудочка, постинфарктным кардиосклерозом и коронарной реваскуляризацией в анамнезе миокардит выявлялся в 69% случаев и представлял собой частое сочетанное заболевание. В отсутствие ишемии миокарда его воспаление может способствовать развитию ОДСН, что следует учитывать при проведении диагностики.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Acute decompensated heart failure (ADHF) in patients with post-infarction cardiosclerosis, even with previously performed optimal coronary revascularization, is typically considered a manifestation of ischemic heart disease progression. However, in clinical practice acute decompensation can also be influenced by non-ischemic mechanisms, including myocarditis. Such a combination of conditions appears particularly significant in patients with reduced left ventricular ejection fraction (LVEF) and a history of coronary revascularization in the absence of signs of ongoing myocardial ischemia.</p></sec><sec><title>Aim</title><p>Aim: To assess the prevalence of myocarditis and myocardial viral antigen expression in patients hospitalized with ADHF, reduced LVEF, post-infarction myocardial fibrosis, and a history of coronary revascularization.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. The study included 26 patients admitted with ADHF. Acute coronary syndrome and other conditions, such as anemia, pneumonia, sepsis, influenza, decompensation of diabetes mellitus, tumors, cachexia, or severe valvular heart stenosis, capable of independently causing HF decompensation were excluded. Median LVEF was 29.5% (IQR 22.0–32.0). All patients underwent transthoracic echocardiography, invasive coronary angiography, and right ventricular endomyocardial biopsy. Histological and immunohistochemical (IHC) analyses were performed to identify myocardial inflammation and viral antigen expression. Endomyocardial biopsy of the right ventricle was performed, with three myocardial samples obtained from each patient, followed by pathohistological and immunohistochemical examination.</p></sec><sec><title>Results</title><p>Results. Myocarditis was diagnosed in 18 patients (69%), including viral myocarditis in 13 (50%), viral-autoimmune myocarditis in 3 (12%), and autoimmune myocarditis in 1 patient (4%). Viral antigen expression in the myocardium was detected in 89% of cases. The frequency of viral antigen detection was as follows: enterovirus – 77%, human herpesvirus type 1 – 8%, type 2 – 8%, type 6 – 50%, Epstein-Barr virus – 23%, cytomegalovirus – 8%; parvovirus B19 and adenovirus were not detected. Viral antigen expression was observed in 94% of patients with myocarditis (except for one case of autoimmune myocarditis) and in 75% of patients without histological signs of myocardial inflammation.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with ADHF, reduced LVEF, post-infarction cardiosclerosis, and a history of coronary revascularization, myocarditis was detected in 69% of cases and represented a frequent comorbid condition. In the absence of myocardial ischemia, inflammation of the myocardium may contribute to the development of ADHF, which should be considered during diagnostic evaluation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>биопсия</kwd><kwd>вирусные антигены</kwd><kwd>миокардит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>coronary artery disease</kwd><kwd>endomyocardial biopsy</kwd><kwd>viral antigens</kwd><kwd>myocarditis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Miró Ò., García Sarasola A., Fuenzalida C. et al. ICA-SEMES Research Group. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. Eur. J. Heart Fail. 2019;21(10):1231–1244. https://doi.org/10.1002/ejhf.1567</mixed-citation><mixed-citation xml:lang="en">Miró Ò., García Sarasola A., Fuenzalida C. et al. ICA-SEMES Research Group. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. Eur. J. Heart Fail. 2019;21(10):1231–1244. https://doi.org/10.1002/ejhf.1567</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chioncel O., Mebazaa A., Harjola V.P. et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur. J. Heart Fail. 2017;19 (10):1242–1254. https://doi.org/10.1002/ejhf.890</mixed-citation><mixed-citation xml:lang="en">Chioncel O., Mebazaa A., Harjola V.P. et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur. J. Heart Fail. 2017;19 (10):1242–1254. https://doi.org/10.1002/ejhf.890</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bacmeister L., Schwarzl M., Warnke S. et al. Inflammation and fibrosis in murine models of heart failure. Basic Res. Cardiol. 2019;114(3):19. https://doi.org/10.1007/s00395-019-0722-5</mixed-citation><mixed-citation xml:lang="en">Bacmeister L., Schwarzl M., Warnke S. et al. Inflammation and fibrosis in murine models of heart failure. Basic Res. Cardiol. 2019;114(3):19. https://doi.org/10.1007/s00395-019-0722-5</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pryds K., Rahbek Schmidt M., Bjerre M. et al. Effect of long-term remote ischemic conditioning on inflammation and cardiac remodeling. Scand. Cardiovasc. J. 2019;53(4):183–191. https://doi.org/10.1080/14017431.2019.1622770</mixed-citation><mixed-citation xml:lang="en">Pryds K., Rahbek Schmidt M., Bjerre M. et al. Effect of long-term remote ischemic conditioning on inflammation and cardiac remodeling. Scand. Cardiovasc. J. 2019;53(4):183–191. https://doi.org/10.1080/14017431.2019.1622770</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Керчева М.А., Рябова Т.Р., Гусакова А.М. Неблагоприятное ремоделирование левого желудочка и сывороточный уровень матриксных металлопротеиназ, маркеров миокардиальной дисфункции и субклинического воспаления у пациентов с острым первичным передним инфарктом миокарда с подъемом сегмента ST. Сибирский журнал клинической и экспериментальной медицины. 2017;32(1):31–35. https://doi.org/10.29001/2073-8552-2017-32-1-31-35</mixed-citation><mixed-citation xml:lang="en">Kercheva M.A., Ryabova T.R., Gusakova A.M. Adverse left ventricular remodeling and the serum levels of matrix metalloproteinases, biomarkers of myocardium dysfunction and inflammation in patients with acute primary anterior STEMI. Siberian Journal of Clinical and Experimental Medicine. 2017;32(1):31–35. (In Russ.) https://doi.org/10.29001/2073-8552-2017-32-1-31-35</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Nappi F. Myocarditis and Inflammatory Cardiomyopathy in Dilated Heart Failure. Viruses. 2025;17(4):484. https://doi.org/10.3390/v17040484</mixed-citation><mixed-citation xml:lang="en">Nappi F. Myocarditis and Inflammatory Cardiomyopathy in Dilated Heart Failure. Viruses. 2025;17(4):484. https://doi.org/10.3390/v17040484</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schulz-Menger J., Collini V., Gröschel J. et al. The ESC Scientific Document Group, 2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC). Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal. 2025. https://doi.org/10.1093/eurheartj/ehaf192</mixed-citation><mixed-citation xml:lang="en">Schulz-Menger J., Collini V., Gröschel J. et al. The ESC Scientific Document Group, 2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC). Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal. 2025. https://doi.org/10.1093/eurheartj/ehaf192</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Olejniczak M., Schwartz M., Webber E. et al. Viral Myocarditis-Incidence, Diagnosis and Management. J. Cardiothorac. Vasc. Anesth. 2020;34(6):1591–1601. https://doi.org/10.1053/j.jvca.2019.12.052</mixed-citation><mixed-citation xml:lang="en">Olejniczak M., Schwartz M., Webber E. et al. Viral Myocarditis-Incidence, Diagnosis and Management. J. Cardiothorac. Vasc. Anesth. 2020;34(6):1591–1601. https://doi.org/10.1053/j.jvca.2019.12.052</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tschöpe C., Ammirati E., Bozkurt B. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 2021;18(3):169–193. https://doi.org/10.1038/s41569-020-00435-x</mixed-citation><mixed-citation xml:lang="en">Tschöpe C., Ammirati E., Bozkurt B. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 2021;18(3):169–193. https://doi.org/10.1038/s41569-020-00435-x</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Кручинкина Е.В., Огуркова О.Н., Гусакова А.М. и др. Особенности течения острой декомпенсации ишемической сердечной недостаточности и/или продолжающегося неблагоприятного ремоделирования левого желудочка у пациентов с выявленным вирусом герпеса человека 6-го типа. Сибирский журнал клинической и экспериментальной медицины. 2021;36(3):111–118. https://doi.org/10.29001/2073-8552-2021-36-3-111-118</mixed-citation><mixed-citation xml:lang="en">Kruchinkina E.V., Ogurkova O.N., Gusakova A.M. et al. Features of the course of acute decompensated ischemic heart failure and/or ongoing adverse left ventricular remodeling in patients with identified human herpes virus type 6. Siberian Journal of Clinical and Experimental Medicine. 2021;36(3):111–118. https://doi.org/10.29001/2073-8552-2021-36-3-111-118</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fujita S., Okamoto R., Takamura T. et al. Fulminant myocarditis in a patient with severe coronary artery disease. J. Cardiol. Cases. 2013;9(1):15–17. https://doi.org/10.1016/j.jccase.2013.08.010</mixed-citation><mixed-citation xml:lang="en">Fujita S., Okamoto R., Takamura T. et al. Fulminant myocarditis in a patient with severe coronary artery disease. J. Cardiol. Cases. 2013;9(1):15–17. https://doi.org/10.1016/j.jccase.2013.08.010</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лутохина Ю.А., Благова О.В., Седов В.П. и др. Сочетание хронического миокардита и прогрессирующей ишемической болезни сердца: дифференциальный диагноз и поэтапное лечение. Российский кардиологический журнал. 2020;25(11):3915. https://doi.org/10.15829/1560-4071-2020-3915</mixed-citation><mixed-citation xml:lang="en">Lutokhina Yu.A., Blagova O.V., Sedov V.P. et al. Combination of chronic myocarditis and progressive coronary artery disease: differential diagnosis and stepwise treatment. Russian Journal of Cardiology. 2020;25(11):3915. https://doi.org/10.15829/29/1560-4071-2020-3915</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Caforio A.L.P., Marcolongo R., Jahns R. et al. Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. Heart Failure Reviews. 2013;18:715–732. https://doi.org/10.1007/s10741-012-9364-5</mixed-citation><mixed-citation xml:lang="en">Caforio A.L.P., Marcolongo R., Jahns R. et al. Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. Heart Failure Reviews. 2013;18:715–732. https://doi.org/10.1007/s10741-012-9364-5</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sagar S., Liu P.P., Cooper L.T. Jr. Myocarditis. Lancet. 2012;379(9817):738–747. https://doi.org/10.1016/S0140-6736(11)60648-X</mixed-citation><mixed-citation xml:lang="en">Sagar S., Liu P.P., Cooper L.T. Jr. Myocarditis. Lancet. 2012;379(9817):738–747. https://doi.org/10.1016/S0140-6736(11)60648-X</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Krych S., Jęczmyk A., Jurkiewicz M. et al. Viral Myocarditis as a Factor Leading to the Development of Heart Failure Symptoms, Including the Role of Parvovirus B19 Infection-Systematic Review. Int. J. Mol. Sci. 2024;25(15):8127. https://doi.org/10.3390/ijms25158127</mixed-citation><mixed-citation xml:lang="en">Krych S., Jęczmyk A., Jurkiewicz M. et al. Viral Myocarditis as a Factor Leading to the Development of Heart Failure Symptoms, Including the Role of Parvovirus B19 Infection-Systematic Review. Int. J. Mol. Sci. 2024;25(15):8127. https://doi.org/10.3390/ijms25158127</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hartman M.H.T., Groot H.E., Leach I.M. et al. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc. Med. 2018;28(6):369–379. https://doi.org/10.1016/j.tcm.2018.02.003</mixed-citation><mixed-citation xml:lang="en">Hartman M.H.T., Groot H.E., Leach I.M. et al. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc. Med. 2018;28(6):369–379. https://doi.org/10.1016/j.tcm.2018.02.003</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shah K.S., Maisel A.S., Fonarow G.C. Troponin in Heart Failure. Heart Fail. Clin. 2018;14(1):57–64. https://doi.org/10.1016/j.hfc.2017.08.007</mixed-citation><mixed-citation xml:lang="en">Shah K.S., Maisel A.S., Fonarow G.C. Troponin in Heart Failure. Heart Fail. Clin. 2018;14(1):57–64. https://doi.org/10.1016/j.hfc.2017.08.007</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">D'Amato A., Severino P., Prosperi S. et al. The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum. J. Clin. Med. 2024;13(12):3533. https://doi.org/10.3390/jcm13123533</mixed-citation><mixed-citation xml:lang="en">D'Amato A., Severino P., Prosperi S. et al. The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum. J. Clin. Med. 2024;13(12):3533. https://doi.org/10.3390/jcm13123533</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
